Market Research Logo

Migraine Pipeline Drugs Market Assessment: Industry Analysis, Pipeline Review, Clinical Trials, Market Potential – Forecast to 2022

Migraine Pipeline Drugs Market Assessment: Industry Analysis, Pipeline Review, Clinical Trials, Market Potential – Forecast to 2022

Executive Summary

The report presents the market potential of seven major pipeline drugs meant for the treatment of migraine. These seven drugs that fall in the various categories of Ergotamines, Anti 5-HT Receptor Agonists and Anti-CGRPs by mechanism of action have been recognized as being clinically effective in migraine treatment. Expected to be launched in the market within the next 4-5 years, these seven potential drugs are likely to bring about major changes in the way migraine is treated globally.

A comprehensive research report created through extensive primary research (inputs from industry experts, companies, stakeholders) and secondary research, the report aims to present the analysis of Global Migraine Pipeline Drugs Market by assessing the potential of the seven drugs that will be launched in the near future. Also, the report assesses the results of various clinical trials undertaken for each of the seven drugs, the product profile, description and regulatory phase of each of the seven drugs. Also, 7Ps Analysis (Patent, Phase, Pathway, Patient, Physician, Payer, Partner) has been done for each of the seven drugs to present the current perspective.

The report titled “Migraine Pipeline Drugs Market Assessment: Industry Analysis, Pipeline Review, Clinical Trials, Market Potential – Forecast to 2022” also analyzes the overall sizing, growth and forecast of Migraine Drugs Market By Type (Acute and Prophylaxis) for the global market as well as for countries including United States, United Kingdom, Japan, France, Italy and Germany.

Over the recent years, the Migraine Drugs market is growing rapidly due to rising prevalence of migraine patients around the world. Globally, the growth of Migraine Drugs market is driven by rising awareness regarding migraine and available treatments

The global migraine drugs market is projected to display a robust growth represented by a CAGR of 14.48% during 2017– 2022, chiefly driven by rising consumption of unhealthy food coupled with unmet need By the present drugs for the treatment of migraine. The report has covered and analysed the present migraine drugs in the market and has also analysed potential of seven major pipeline drugs. The report intends to provide cutting-edge market intelligence and help decision makers take sound investment evaluation. Besides, the report also identifies and analyses the emerging trends along with major drivers, challenges and opportunities in the global migraine pipeline drugs market.

Scope of the Report

Migraine Pipeline Drugs Assessment - Drug X1, X2, X3, X4, X5, X6, X7 (Forecast Period: 2019-2022)

- Market Potential

- Clinical Trials

- Product Description

- Regulatory Phases

- 7Ps Analysis

Global Migraine Drugs Market (Actual Period: 2012-2016, Forecast Period: 2017-2022)

- Market Sizing and Growth

- Market Sizing and Growth By Type - Acute and Prophylaxis

Country Analysis US, UK, Japan, France, Italy, Germany (Actual Period: 2012-2016, Forecast Period: 2017-2022)

- Market Sizing and Growth

Other Report Highlights

- Market Dynamics - Drivers, Challenges

- Company Analysis - Amgen Biopharmaceuticals, Allergan, Eli Lilly, Alder Pharmaceuticals, Teva Pharmaceutical, Vernalis, Pfizer, Impax Laboratories, Glaxo Smithkline

Customization of the Report

The report could be customized according to the client s specific research requirements. No additional cost will be required to pay for limited additional research.


1. Research Methodology
2. Executive Summary
3. Migraine - An Overview
3.1. Symptoms of migraine
3.2. Stages of Migraine
3.3. Types of Migraine
3.4. Types of migraine on the basis of frequency of occurrence
4. Treatment of Migraine
4.1. Goal of Migraine Treatment
4.2. Treatment of Migraine - Pharmacological and Non-Pharmacological
4.2.1. Pharmacological treatment of migraine
4.2.2. Pharmacological - Abortive
4.2.3. Pharmacological - Preventive
4.2.4. Non-Pharmacological Treatment of Migraine
4.2.5. Non- Pharmacological - Surgical
4.2.6. Non- Pharmacological - Non-Surgical
5. Anti-Migraine Pipeline Drugs Analysis
5.1. Anti-Migraine Pipeline Drugs (According to Mechanism of Working)
5.2. Anti-Migraine Pipeline Drugs (Ergotamine): Drug - X1
5.2.1. Description
5.2.2. Regulatory Milestones
5.2.3. Advantages & Disadvantages
5.2.4. Product Profile & Expected Launch
5.2.5. Clinical Trials and Status
5.2.6. Pivotal Clinical Trials and Results
Table 1: 2 hour pain relief & pain free rates in patients treated with LEVADEX (MAP0004) compared to placebo (1st pivotal trial)
Table 2: Improvement at two hours in people who took LEVADEX compared to Placebo (2nd pivotal trial)
5.2.7. Drug X-1- Global Market Potential
Table 3: Global Semprana/ Levadex Market Size, By Value, Forecast, 2019-2022 (USD Billion)
5.2.8. Drug X-1- 7Ps Analysis
5.3. Anti-Migraine Pipeline Drugs (Anti-5HT Receptor Agonist): Drug - X2
5.3.1. Description
5.3.2. Regulatory Milestones
5.3.3. Advantages & Disadvantages
5.3.4. Product Profile & Expected Launch
5.3.5. Clinical Trials and Status
Table A: Summary of Completed Clinical Trials of Lasmiditan
Table B: Summary of Completed & ongoing Clinical Trials of Lasmiditan
Table C: Summary of Completed & ongoing Clinical Trials of IV Lasmiditan
5.3.6. Pivotal Clinical Trials and Results
Table 4: Percentage of patients achieving primary end point
Table D: Number and percentage of patients who reported each particular TEAE with safety population for each dose.
Table 5: Percentage of patients achieving secondary endpoint
5.3.7. Drug - X2 - Global Market Potential
Table 6: Global Lasmiditan Market Size, By Value, Forecast, 2019-2022 (USD Million)
5.3.8. Drug - X2 - 7Ps Analysis
5.4. Anti-Migraine Pipeline Drugs (Anti CGRPs)
5.5. Anti-Migraine Pipeline Drugs (Anti CGRPs) - By Drug
5.6. Anti-Migraine Pipeline Drugs (CGRP Antagonist): Drug - X3
5.6.1. Description
5.6.2. Regulatory Milestones
5.6.3. Advantages & Disadvantages
5.6.4. Product Profile & Expected Launch
5.6.5. Clinical Trials and Status
Table E: Summary of Completed & ongoing Clinical Trials of Ubrogepant
5.6.6. Pivotal Clinical Trials and Results
Table 7: Efficacy in 2 hour pain freedom
5.6.7. Drug - X3 - Global Market Potential
Table 8: Global Ubrogepant Market Size, By Value, Forecast, 2019-2022 (USD Million)
5.6.8. Drug - X3 - 7Ps Analysis
5.7. Anti-Migraine Pipeline Drugs (Anti-CGRP Mab): Drug - X4
5.7.1. Description
5.7.2. Regulatory Milestones
5.7.3. Advantages & Disadvantages
5.7.4. Product Profile & Expected Launch
5.7.5. Clinical Trials and Status
Table F: Summary of Completed & ongoing Clinical Trials of Eptinezumab
5.7.6. Pivotal Clinical Trials and Results
Table 9: Reduction in Monthly migraine days – weeks 1 through 12
Table 10: Percentage of patients with =75% reduction in number of migraine days – weeks 1 through 24
Table 11: Percentage of patients with 100% response rate (no migraine in any given month) – months 1 through 6
5.7.7. Drug - X4 - Global Market Potential
Table 12: Global Eptinezumab Market Size, By Value, Forecast, 2019-2022 (USD Million)
5.7.8. Drug - X4 - 7Ps Analysis
5.8. Anti-Migraine Pipeline Drugs (Anti-CGRP Mab): Drug - X5
5.8.1. Description
5.8.2. Regulatory Milestones
5.8.3. Advantages & Disadvantages
5.8.4. Product Profile & Expected Launch
5.8.5. Clinical Trials and Status
Table G: Summary of Completed Clinical Trials of Galcanezumab
Table H: Summary of Ongoing Clinical Trials of Galcanezumab
5.8.6. Pivotal Clinical Trials and Results
5.8.7. Drug - X5 - Global Market Potential
Table 13: Global Galcanezumab Market Size, By Value, Forecast, 2019-2022 (USD Million)
5.8.8. Drug - X5 - 7Ps Analysis
5.9. Anti-Migraine Pipeline Drugs (Anti-CGRP Mab): Drug - X6
5.9.1. Description
5.9.2. Regulatory Milestones
5.9.3. Advantages & Disadvantages
5.9.4. Product Profile & Expected Launch
5.9.5. Clinical Trials and Status
Table I: Summary of Completed & Ongoing Clinical Trials of Fremanezumab
5.9.6. Pivotal Clinical Trials and Results
5.9.7. Drug - X6 - Global Market Potential
Table 14: Global Fremanezumab Market Size, By Value, Forecast, 2019-2022 (USD Million)
5.9.8. Drug - X6 - 7Ps Analysis
5.10. Anti-Migraine Pipeline Drugs (Anti-CGRP Mab): Drug - X7
5.10.1. Description
5.10.2. Regulatory Milestones
5.10.3. Advantages & Disadvantages
5.10.4. Product Profile & Expected Launch
5.10.5. Clinical Trials and Status
Table J: Summary of Completed & Ongoing Clinical Trials of Erenumab
Table 15: Monthly migraine days reduction vs placebo in previous prophylactic drugs failure group
Table 16: Reduction in days using acute pain medications in recent drug overuse group
5.10.6. Pivotal Clinical Trials and Results
5.10.7. Drug - X7 - Global Market Potential
Table 17: Global Erenumab Market Size, By Value, Forecast, 2019-2022 (USD Million)
5.10.8. Drug - X7 - 7Ps Analysis
6. Global Migraine Drugs Market: Growth and Forecast
6.1. By Value (2012-2016)
Table 18: Global Migraine Drugs Market Size, By value, 2012-2016 (USD Billion)
6.2. By Value (2017-2022)
Table 19: Global Migraine Drugs Market Size, By Value, Forecast, 2017-2022 (USD Billion)
Table 20: Global consumption of chocolate confectionary, By volume (in 1000 metric tones)
7. Global Migraine Drugs Market - Analysis By Type
7.1. Global Migraine Drugs Market, By Type: Breakdown (%)
7.1.1. Global Migraine Drugs Market- By Type: 2016 (%)
Table 21: Global Migraine Drugs Market Share, By Type, 2016 (%)
7.1.2. Global Migraine Drugs Market By Type: 2022 (%)
Table 22: Global Migraine Drugs Market Share, By Type, 2022 (%)
7.2. Global Migraine Drugs Market- By Acute
7.2.1. By Value (2012-2016)
Table 23: Global Migraine Drugs Market, By Acute, By Value, 2012-2016 (USD Million)
7.2.2. By Value (2017-2022)
Table 24: Global Migraine Drugs Market, By Acute, By Value, 2017-2022 (USD Million)
7.3. Global Migraine Drugs Market- By Prophylaxis
7.3.1. By Value (2012-2016)
Table 25: Global Migraine Drugs Market, By Prophylaxis, By Value, 2012-2016 (USD Million)
7.3.2. By Value (2017-2022)
Table 26: Global Migraine Drugs Market, By Prophylaxis, By Value, 2017-2022 (USD Million)
8. Global Migraine Drugs Market: Country Analysis (U.S, U.K, Japan, France, Italy, Germany, ROW)
8.1. U.S. Migraine Drugs Market, By Value (2012-2022)
Table 27: U.S. Migraine Drugs Market, By Value, 2012-2016 (USD Billion)
Table 28: U.S. Migraine Drugs Market, By Value, 2017-2022 (USD Billion)
Table 29: U.S Adult Migraine Patients, In Percentage
Table 30: U.S Migraine Patients, By gender, In Percentage
8.2. U.K. Migraine Drugs Market, By Value (2012-2022)
Table 31: U.K Migraine Drugs Market, By Value, 2012-2016 (USD Billion)
Table 32: U.K. Migraine Drugs Market, By Value, 2017-2022 (USD Billion)
Table 33: U.K. Migraine Patient, In Percentage
Table 34: NHS Budget for mental illness, In Billion
8.3. Japan Migraine Drugs Market, By Value (2012-2022)
Table 35: Japan Migraine Drugs Market, By Value, 2012-2016 (USD Billion)
Table 36: Japan Migraine Drugs Market, By Value, 2017-2022 (USD Billion)
Table 37: Japan Migraine Patient out of total population, In Percentages
8.4. France Migraine Drugs Market, By Value (2012-2022)
Table 38: France Migraine Drugs Market, By Value, 2012-2016 (USD Billion)
Table 39: France Migraine Drugs Market, By Value, 2017-2022 (USD Billion)
Table 40: France Migraine Patient, In Percentage
Table 41: Unemployment rate in France in percentage
8.5. Italy Migraine Drugs Market, By Value (2012-2022)
Table 42: Italy Migraine Drugs Market, By Value, 2012-2016 (USD Billion)
Table 43: Italy Migraine Drugs Market, By Value, 2017-2022 (USD Billion)
Table 44: Italy Migraine Patient out of total population, In Percentages
Table 45: Italy Unemployment rate, In Percentages
8.6. Germany Migraine Drugs Market, By Value (2012-2022)
Table 46: Germany Migraine Drugs Market, By Value, 2012-2016 (USD Billion)
Table 47: Germany Migraine Drugs Market, By Value, 2017-2022 (USD Billion)
Table 48: Germany Migraine Patient out of total population, In Percentages
Table 49: First Time asylum application, In Number
Table 50: ROW Migraine Drugs Market, By Value, 2012-2016 (USD Billion)
Table 51: ROW Migraine Drugs Market, By Value, 2017-2022 (USD Billion)
8.7. ROW Migraine Drugs Market, By Value (2012-2022)
9. Market Dynamics
9.1. Migraine Drug Market Drivers
9.2. Migraine Drug Market Challenges
10. Company Profiles
10.1. Amgen
10.2. Allergan
Table 52: Total global sales of Allergan's Botox in 2016 and forecasted for 2022 (USD Million)
10.3. Eli Lilly
10.4. Alder Pharmaceuticals
10.5. Teva Pharmaceuticals
10.6. Vernalis
10.7. Pfizer
10.8. Impax Laboratories
10.9. Glaxo Smithkline

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report